Clinical Trial Update: A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical study evaluating CT1194C in relapsed/refractory B-cell non-Hodgkin lymphoma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CT1194C

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING